Neuromuscular Disorders
Ulysses Neuroscience offers specialised biomarker services for neuromuscular disorders, with particular expertise in cytoskeletal dynamics and axonal integrity markers. Our validated assays for α-tubulin post-translational modifications provide unique insights into microtubule function and axonal transport—processes critically affected in inherited peripheral neuropathies. Through our collaboration with leading clinical centres including San Raffaele Hospital, we bridge preclinical biomarker discovery with patient sample analysis, delivering translational data that informs therapeutic development and clinical trial design.
Explore Our Full Therapeutic Expertise
Beyond neuropsychiatric disorders, Ulysses Neuroscience delivers comprehensive preclinical and translational services across the spectrum of CNS conditions. Our integrated platform—combining behavioural pharmacology, advanced biomarker technologies, EEG, and human iPSC-derived models—enables seamless translation from bench to bedside across multiple therapeutic areas.
Neuropsychiatric
Diseases
- Depression & Treatment-Resistant Depression
- Anxiety Disorders
- Schizophrenia
Neurodegenerative Diseases
- Alzheimer’s Disease
- Parkinson’s Disease
- Multiple Sclerosis
- Amyotrophic Lateral Sclerosis (ALS)
Neuromuscular
Diseases
- Charcot-Marie-Tooth Disease (CMT)
Neurodevelopmental Diseases
- CDKL5 Deficiency Disorder (CDD)
- Fragile X Syndrome (FXS)
- Epilepsy & Seizure Disorders
Psychedelics and
Neuroplastogens
- Classical psychedelics
- Next-generation non-hallucinogenic neuroplastogens.
